PROMEDIGEN

Hee-Sung Park, Ph.D., Founder & CEO

Hee-Sung is a professor of chemistry at the Korea Advanced Institute of Science and Technology (KAIST). As a leading scholar in the field, Hee-Sung has published numerous critical research articles and inspiring breakthroughs in scientific journals including four papers in SCIENCE. In particular, Hee-Sung has invented innovative protein engineering technologies including site-specific incorporation of phosphoserine (published in SCIENCE in 2011) and chemical biology routes to site-specific authentic protein modifications (published in SCIENCE in 2016). He founded a the biotech company Promedigen in 2019 based on such state-of-the-art scientific advances. Hee-Sung believes that these pioneering technologies will revolutionize drug discovery and lead to the development of new drugs for cancer and neurogenerative diseases.

Seung-chul LeeStrategic Director & a Board Member

Seung-chul is a Strategic Director and a board member of Promedigen. Prior to Promedigen, He worked as a Chief Investment Officer at BE investment and has worked as a venture capitalist at APL Partners. His career is specialized in biopharmaceutical investment and IPO strategies. He earned his B.S. & M.S. in Food Molecular Microbiology from Seoul National University.

Kyu-Kwang Cho, Ph.D.,R&D General Manager

Kyu-Kwang is R&D General Manager of Promedigen. He is interested in development of drug screening platform for targeting protein-protein interaction and hit validation. He earned his Ph.D. degree in Department of Chemistry from Korea Advanced Institute of Science and Technology(KAIST).

Su-Jung Bae, Ph.D.,Efficacy Team Leader

Su-Jung is a Efficacy team leader of promedigen. Dr. Bae was a researcher in the Drug Development Research Department at the Korea Research Institute of Chemical Technology, KRICT. She received her M.S. and Ph.D. in Pharmacy from Ewha Womans University

Ji-Ryang HeoGeneral Manager

Ji-Ryang is currently a General Manager in Management Department. He is in charge of finance, accounting and general affairs as well. Before joining Promedigen, he has worked in the field of accounting for 15 years. He earned his Bachelor of Business Administration from Pusan National University.

Hiroaki Suga, Ph.D.,Scientific Advisory Board

• Professor, The University of Tokyo
• Founder of PeptiDream (market cap of $2 bn)
• Advising on protein engineering, chemical biology and venture creation

Byung-Ha Oh, Ph.D.,Scientific Advisory Board

• Professor of Biological Sciences, KAIST
• Previously at GSK
• Advising on structural biology